{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:26:37Z","timestamp":1790245597755,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma &amp; Immunology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.anai.2010.01.021","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T04:56:25Z","timestamp":1267505785000},"page":"286-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Underexpression and overexpression of Fas and Fas ligand: a double-edged sword"],"prefix":"10.1016","volume":"104","author":[{"given":"Shahid R.","family":"Randhawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem G.","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Lowery-Nordberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Cotelingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian M.","family":"Casillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2010.01.021_bib1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br J Cancer"},{"key":"10.1016\/j.anai.2010.01.021_bib2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ceb.2004.09.011","article-title":"Death by design: apoptosis, necrosis and autophagy","volume":"16","author":"Edinger","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.anai.2010.01.021_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-4615-5355-7_14","article-title":"In vivo dynamics of anti-viral CD8 T cell responses to different epitopes: an evaluation of bystander activation in primary and secondary responses to viral infection","volume":"452","author":"Murali-Krishna","year":"1998","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.anai.2010.01.021_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1074-7613(00)80469-0","article-title":"Massive expansion of antigen-specific CD8+ T cells during an acute virus infection","volume":"8","author":"Butz","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.anai.2010.01.021_bib5","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.4049\/jimmunol.149.11.3753","article-title":"Differential expression of apoptosis-related Fas antigen on lymphocyte subpopulations in human peripheral blood","volume":"149","author":"Miyawaki","year":"1992","journal-title":"J Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.V84.4.1201.1201","article-title":"Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils","volume":"84","author":"Iwai","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.anai.2010.01.021_bib7","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/sj.cdd.4402101","article-title":"ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death","volume":"14","author":"Schulte","year":"2007","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.anai.2010.01.021_bib8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0092-8674(00)81266-0","article-title":"FLICE, a novel FADD-homologous ICE\/CED-3-like protease, is recruited to the CD95 (Fas\/APO-1) death--inducing signaling complex","volume":"85","author":"Muzio","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.anai.2010.01.021_bib9","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0022-3476(67)80262-2","article-title":"Chronic lymphadenopathy simulating malignant lymphoma","volume":"70","author":"Canale","year":"1967","journal-title":"J Pediatr"},{"key":"10.1016\/j.anai.2010.01.021_bib10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1126\/science.7539157","article-title":"Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity","volume":"268","author":"Rieux-Laucat","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.anai.2010.01.021_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0092-8674(95)90013-6","article-title":"Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome","volume":"81","author":"Fisher","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.anai.2010.01.021_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.7326\/0003-4819-130-7-199904060-00020","article-title":"An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome","volume":"130","author":"Straus","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.anai.2010.01.021_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/intimm\/10.2.195","article-title":"Novel Fas (CD95\/APO-1) mutations in infants with a lymphoproliferative disorder","volume":"10","author":"Kasahara","year":"1998","journal-title":"Int Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib14","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1203\/00006450-200003000-00009","article-title":"Autoimmune lymphoproliferative syndrome (ALPS) in a child from consanguineous parents: a dominant or recessive disease?","volume":"47","author":"van der Burg","year":"2000","journal-title":"Pediatr Res"},{"key":"10.1016\/j.anai.2010.01.021_bib15","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1086\/302333","article-title":"Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance","volume":"64","author":"Jackson","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.anai.2010.01.021_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1172\/JCI5121","article-title":"The molecular basis for apoptotic defects in patients with CD95 (Fas\/Apo-1) mutations","volume":"103","author":"Vaishnaw","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2010.01.021_bib17","first-page":"2575","article-title":"Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations","volume":"94","author":"Rieux-Laucat","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.anai.2010.01.021_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev.immunol.24.021605.090513","article-title":"Genetic disorders of programmed cell death in the immune system","volume":"24","author":"Bidere","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa040036","article-title":"Autoimmune lymphoproliferative syndrome with somatic Fas mutations","volume":"351","author":"Holzelova","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2010.01.021_bib20","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1172\/JCI118892","article-title":"Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease","volume":"98","author":"Wu","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anai.2010.01.021_bib21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2006-04-015776","article-title":"A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome","volume":"108","author":"Del-Rey","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.anai.2010.01.021_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0952-7915(03)00042-6","article-title":"Cell-death signaling and human disease","volume":"15","author":"Rieux-Laucat","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/sj.cdd.4401190","article-title":"Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways","volume":"10","author":"Rieux-Laucat","year":"2003","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.anai.2010.01.021_bib24","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature01063","article-title":"Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency","volume":"419","author":"Chun","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.anai.2010.01.021_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11882-003-0070-1","article-title":"Immune disorders caused by defects in the caspase cascade","volume":"3","author":"Puck","year":"2003","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.anai.2010.01.021_bib26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0092-8674(00)80605-4","article-title":"Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II","volume":"98","author":"Wang","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.anai.2010.01.021_bib27","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1073\/pnas.0702975104","article-title":"NRAS mutation causes a human autoimmune lymphoproliferative syndrome","volume":"104","author":"Oliveira","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anai.2010.01.021_bib28","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood.V95.10.3176","article-title":"Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer","volume":"95","author":"Ramenghi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.anai.2010.01.021_bib29","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1182\/blood.V89.4.1341","article-title":"Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis","volume":"89","author":"Sneller","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.anai.2010.01.021_bib30","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V98.1.194","article-title":"The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis","volume":"98","author":"Straus","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.anai.2010.01.021_bib31","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10428190310001593166","article-title":"Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations","volume":"45","author":"Poppema","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.anai.2010.01.021_bib32","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1081-1206(10)60740-5","article-title":"Autoimmune lymphoproliferative syndrome in a patient with common variable immunodeficiency: dichotomy of apoptosis","volume":"98","author":"Narra","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib33","first-page":"538","article-title":"The broad spectrum of autoimmune lymphoproliferative disease: molecular bases, clinical features and long-term follow-up in 31 patients","volume":"91","author":"Campagnoli","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.anai.2010.01.021_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cyto.b.10007","article-title":"Human B cells express a CD45 isoform that is similar to murine B220 and is downregulated with acquisition of the memory B-cell marker CD27","volume":"51","author":"Bleesing","year":"2003","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.anai.2010.01.021_bib35","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1046\/j.1365-2141.2003.04034.x","article-title":"Common expression of an unusual CD45 isoform on T cells from patients with large granular lymphocyte leukaemia and autoimmune lymphoproliferative syndrome","volume":"120","author":"Bleesing","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.anai.2010.01.021_bib36","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/cimm.2001.1865","article-title":"Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis","volume":"213","author":"Bleesing","year":"2001","journal-title":"Cell Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib37","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.anai.2010.01.021_bib38","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2008.06.013","article-title":"Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment","volume":"122","author":"Murata","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2133.1996.tb06976.x","article-title":"Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis","volume":"134","author":"Paul","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.anai.2010.01.021_bib40","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anai.2010.01.021_bib41","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2010.01.021_bib42","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11604-008-0297-9","article-title":"Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases","volume":"27","author":"Musio","year":"2009","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.anai.2010.01.021_bib43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1525-1470.2002.00002.x","article-title":"Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy","volume":"19","author":"Samimi","year":"2002","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.anai.2010.01.021_bib44","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/archinte.1992.00400190131024","article-title":"Herpes simplex virus associated with recurrent Stevens-Johnson syndrome: a management strategy","volume":"152","author":"Detjen","year":"1992","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.anai.2010.01.021_bib45","doi-asserted-by":"crossref","first-page":"e1002","DOI":"10.1542\/peds.2006-2401","article-title":"Mycoplasma pneumoniae and atypical Stevens-Johnson syndrome: a case series","volume":"119","author":"Ravin","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.anai.2010.01.021_bib46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00006454-200102000-00022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system","volume":"20","author":"Ball","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"2 pt 1","key":"10.1016\/j.anai.2010.01.021_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0190-9622(96)90320-5","article-title":"Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease","volume":"35","author":"Langley","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2010.01.021_bib48","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2230.2008.03029.x","article-title":"Increased caspase-3 and altered expression of apoptosis-associated proteins, Bcl-2 and Bax in lichen planus","volume":"34","author":"Abdel-Latif","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.anai.2010.01.021_bib49","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/jid.2009.14","article-title":"Targeting apoptosis defects in cutaneous T-cell lymphoma","volume":"129","author":"Contassot","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2010.01.021_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.imlet.2005.06.008","article-title":"Role of apoptosis in basal cell and squamous cell carcinoma formation","volume":"100","author":"Erb","year":"2005","journal-title":"Immunol Lett"},{"key":"10.1016\/j.anai.2010.01.021_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2249.2006.03086.x","article-title":"Polyclonal expansion of large granular lymphocytes in common variable immunodeficiency: association with neutropenia","volume":"144","author":"Holm","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/leu.2008.329","article-title":"Inhibitor of apoptosis proteins in hematological malignancies","volume":"23","author":"Fulda","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.anai.2010.01.021_bib53","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ijc.24064","article-title":"Tumor resistance to apoptosis","volume":"124","author":"Fulda","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anai.2010.01.021_bib54","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/sj.cdd.4402182","article-title":"Apoptosis in the development of the immune system","volume":"15","author":"Opferman","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.anai.2010.01.021_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7150\/ijms.5.169","article-title":"Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis","volume":"5","author":"Fries","year":"2008","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.anai.2010.01.021_bib57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1196\/annals.1361.095","article-title":"Increased spontaneous apoptosis of CD4+CD25+ T cells in patients with active rheumatoid arthritis is reduced by infliximab","volume":"1051","author":"Toubi","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.anai.2010.01.021_bib58","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.anai.2010.01.021_bib59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ni0503-410","article-title":"Apoptosis in the development and maintenance of the immune system","volume":"4","author":"Opferman","year":"2003","journal-title":"Nat Immunol"},{"issue":"suppl 1","key":"10.1016\/j.anai.2010.01.021_bib60","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1002\/eji.200737462","article-title":"How apoptosis got the immune system in shape","volume":"37","author":"Feig","year":"2007","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/039463200201500301","article-title":"Oxidative stress and apoptosis in immune diseases","volume":"15","author":"Agostini","year":"2002","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.anai.2010.01.021_bib62","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.0105-2896.2005.00261.x","article-title":"Molecular mechanisms of apoptosis in the cells of the immune system in human aging","volume":"205","author":"Gupta","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.anai.2010.01.021_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0897.2008.00583.x","article-title":"Placental fas\/fas ligand expression in early pregnancy losses","volume":"60","author":"Guvendag Guven","year":"2008","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.anai.2010.01.021_bib64","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0301-472X(03)00109-7","article-title":"Clinical relevance of CD95 (Fas\/Apo-1) on T cells of patients with B-cell chronic lymphocytic leukemia","volume":"31","author":"Groneberg","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.anai.2010.01.021_bib65","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/1529-0131(199909)42:9<1833::AID-ANR7>3.0.CO;2-Q","article-title":"The spectrum of apoptotic defects and clinical manifestations, including systemic lupus erythematosus, in humans with CD95 (Fas\/APO-1) mutations","volume":"42","author":"Vaishnaw","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.anai.2010.01.021_bib66","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00787227","article-title":"Clinical effects of mutations to CD95 (Fas): relevance to autoimmunity?","volume":"19","author":"de Villartay","year":"1998","journal-title":"Springer Semin Immunopathol"},{"key":"10.1016\/j.anai.2010.01.021_bib67","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1034\/j.1600-0609.2000.9o096.x","article-title":"Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura","volume":"64","author":"Yoshimura","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.anai.2010.01.021_bib68","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.410430120","article-title":"Increased serum levels of soluble CD95 (APO-1\/Fas) in relapsing-remitting multiple sclerosis","volume":"43","author":"Zipp","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.anai.2010.01.021_bib69","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1086\/515700","article-title":"Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons","volume":"178","author":"Hosaka","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1016\/j.anai.2010.01.021_bib70","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0002-9440(10)65191-7","article-title":"Involvement of soluble CD95 in Churg-Strauss syndrome","volume":"155","author":"Muschen","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anai.2010.01.021_bib71","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jdermsci.2008.06.003","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases","volume":"52","author":"Abe","year":"2008","journal-title":"J Dermatol Sci"}],"container-title":["Annals of Allergy, Asthma &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120610002152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120610002152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:38:02Z","timestamp":1761050282000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120610002152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S1081120610002152"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2010.01.021","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underexpression and overexpression of Fas and Fas ligand: a double-edged sword","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2010.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}